IBB250516C119000
- 0.40
- -3.70-90.24%
iShares Biotechnology ETF Newsroom
Disdained by the market! Goldman Sachs: Today's pharmaceutical stocks are like "Coal Industrial Concept during the ESG peak period".
Goldman Sachs traders believe that the current trading performance of pharmaceutical stocks resembles "Energy stocks at the peak of the ESG era - as if they are about to perish," with the Sector's valuation relative to the S&P 500 Index having fallen to a historic low, creating the largest discount on record.
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030
Shares of Pharmaceutical Stocks Are Trading Lower. The Sector May Down on Continued Weakness Amid President Trump's Drug Pricing Executive Order.
Beyond The Numbers: 16 Analysts Discuss Regeneron Pharmaceuticals Stock
Sector Update: Health Care Stocks Rise Premarket Wednesday
This Biotech's Stock Rockets on Oral Obesity Drug Partnership With Wegovy Parent
This PVH Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Regeneron Pharmaceuticals Analyst Ratings
$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today
A Look Into Mettler-Toledo Intl Inc's Price Over Earnings
Tamboran And Daly Waters Energy Sign Binding Agreement To Finalize Checkerboard Of Joint Acreage Position Across EPs 76, 98 And 117; DWE To Buy Non-Operating, Non-Controlling Interest In 100,000 Acres For US$15M
Sector Update: Health Care Stocks Mixed Premarket Tuesday
This Caterpillar Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Argenx Analyst Ratings
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of Key Inflation Data
Astellas CEO on Outlook Ahead of Trump's Pharma Tariffs
"Don't sell if prices don't drop!" Trump enforces a mandatory minimum drug price for developed countries, but a lawsuit battle may be "reenacted".
① An executive order signed on the 12th of October, USA time, requires that the payment price of pharmaceuticals in the USA be forcibly anchored to the lowest level of other developed countries within 30 days; ② There is strong opposition within the USA, and industry experts estimate that a legal battle is about to "replay"; ③ As the market-oriented USA begins to wield the big stick of administrative pricing, the underlying rules of the game for Innovative Drugs have quietly been rewritten.
Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today
The "Most-Favored-Nation Pricing" policy for Trump Medicine has been issued: benchmarked against developed countries, complete the Quote within 30 days.
① This policy aims to align prescription drug pricing in the USA with that of "Other developed countries". Trump has requested that the Quote be completed within 30 days; ② The scope of affected Pharmaceuticals is still unclear, and the White House has stated that the government will pay special attention to drugs that have the "largest price differences and highest spending"; ③ Trump had implemented a similar policy before the end of his last term, but it was blocked by the courts and ultimately fell through.
Pharma Stocks Gain as Traders Have Doubts on Trump's Executive Order to Lower Drug Prices